Calls Purchased on Nabi Biopharmaceuticals

Shares of Nabi Biopharmaceuticals NABI are higher on the session by 2.52%, currently trading at $4.89. The stock has been moving largely lower over the past two months and is currently trading below the 200-day moving average. Options traders are buying calls on the name today. A short while ago the December 2011 $7.50 call was purchased 1,000 times, on the offer, on open interest of 433 contracts. Overall call volume is now running at 30.86x the daily average with 95% of all calls traded being purchases on the offer. Nabi Biopharmaceuticals is a biopharmaceutical company focused on the development of vaccines addressing unmet medical needs in the areas of nicotine addiction and infectious disease. As of December 31, 2009, the company's product in development is Nicotine Conjugate Vaccine (NicVAX), a investigational vaccine for treatment of nicotine addiction and prevention of smoking relapse.